In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...

While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the ...

According to the new analysis, performed with a data cut-off in June 2026, the overall survival (OS) hazard ratio in the ...

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...

A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...

Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...

Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public ...

Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling ...

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...

Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has ...

Aerospace technology company Redwire—which has partnered with Bristol Myers Squibb and Eli Lilly to test drug manufacturing in space—has opened a new 30,000 square foot research and microgravity ...